Emotra AB (“Emotra”) has had an eventful spring. New data which show that EDOR® can identify patients with an increased risk of depressive relapse are turning out to be more and more important. Emotra is now increasingly engaged in discussions with psychiatric research centres concerning collaborations to verify these findings and identify new application areas for our method. We have submitted a patent application to protect our application in this new indication area.

 

190620 – Emotra -Nyhetsbrev – New focus areas and more research collaborations